United Kingdom (UK)
Recombinant monoclonal antibody to Gn. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma Mab-1 (23A8-1).
UniProt Accession Number of Target Protein: P21401
Alternative Name(s) of Target: RVFV Gn; p78; Glycoprotein G1; Glycoprotein N
Immunogen: The original antibody was generated by immunizing mice with bacterially produced RVFV Gn protein.
Specificity: The antibody is specific for the Gn protein binding a linear epitope in the B structural domain (aa 366 to 440). Gn is a surface glycoprotein of RVFV.
Application Notes: The specificity of the original format of the antibody to Gn from RVFV lysate was confirmed by ELISA analysis (EC = 3.9 ng/mL). The antibody was potently neutralizing, with an IC50 of 28 ng/ml. To determine the protective potential of the IgG1 format of the antibody, it was administrated to C57BL/6 mice in a RVFV lethal challenge model. The antibody was able to protect the mice, with only one mouse succumbing to disease. The IgG2a version of the antibody was constructed. It exhibited an RVFV neutralization capacity and ELISA affinity similar to that of its IgG1 counterpart. Further, the IgG2a version showed significantly higher NK cell degranulation. In vivo experiments demonstrated that the IgG2a format of the antibody fully protected mice from the lethal challenge (Cartwright et al., 2021; PMID:34494884).
Antibody first published in:
Cartwright et al. Isotype-specific Fc effector functions enhance antibody-mediated Rift Valley Fever virus protection in vivo. mSphere. 2021 Oct 27;6(5):e0055621. PMID:34494884
Note on publication:
The original paper describes the generation and characterization of the antibody.